To examine the potential contribution of precursor substrates to renal gluconeogenesis during hypoglycemia, 14 healthy subjects had arterialized hand vein and renal vein (under fluoroscopy) catheterized after an overnight fast. Net renal balance of lactate, glycerol, alanine, and glutamine was determined simultaneously with systemic and renal glucose kinetics using arteriovenous concentration differences and 6-[ ) during hypoglycemia versus euglycemia (P < 0.05) could account for nearly 60% of all glucose carbons released in the renal vein during hypoglycemia. Our data indicate that extraction of circulating gluconeogenic precursors by the kidney is enhanced and responsible for a substantial fraction of the compensatory rise in RGP during sustained hypoglycemia. Increased renal gluconeogenesis from circulating substrates represents an additional physiological mechanism by which the decrease in blood glucose concentration is attenuated in humans. Diabetes
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To examine the potential contribution of precursor substrates to renal gluconeogenesis during hypoglycemia, 14 healthy subjects had arterialized hand vein and renal vein (under fluoroscopy) catheterized after an overnight fast. Net renal balance of lactate, glycerol, alanine, and glutamine was determined simultaneously with systemic and renal glucose kinetics using arteriovenous concentration differences and 6-[ ) during hypoglycemia versus euglycemia (P < 0.05) could account for nearly 60% of all glucose carbons released in the renal vein during hypoglycemia. Our data indicate that extraction of circulating gluconeogenic precursors by the kidney is enhanced and responsible for a substantial fraction of the compensatory rise in RGP during sustained hypoglycemia. Increased renal gluconeogenesis from circulating substrates represents an additional physiological mechanism by which the decrease in blood glucose concentration is attenuated in humans. Diabetes 49:1186-1193, 2000 D uring hypoglycemia, various counterregulatory hormones are released that blunt insulin action by simultaneously limiting peripheral glucose utilization and increasing glucose production (1) . Earlier studies have demonstrated that hepatic glycogenolysis is responsible for the initial increase in glucose production, whereas gluconeogenesis is the primary process by which glucose production is sustained when hypoglycemia is prolonged (2-4). Recent findings (5, 6) have indicated that the kidney, in addition to the liver, makes a significant contribution to glucose counterregulation. This is not surprising because glucose production in the kidney (analogous to that in the liver) is suppressed by insulin (7) and stimulated by catecholamines (8) . Although substantial in vitro evidence exists that cells of the proximal convoluted tubule are able to efficiently convert 3-carbon precursors and glutamine to glucose (9, 10) , the in vivo data are less conclusive.
The ability of the mammalian kidney to form glucose from noncarbohydrate precursors was first described in humans by Aber et al. (11) . The metabolic pathways and enzymatic steps of renal gluconeogenesis reflect largely those found in the liver of the same species; however, several differences between the liver and the kidney regarding substrate specificity are apparent. Although lactate and glycerol are common substrates for both organs (7, (12) (13) (14) (15) , alanine conversion to glucose takes place almost exclusively in the liver, whereas glutamine conversion to glucose occurs predominantly in the kidney (16, 17) . The potential contribution of these precursors to renal gluconeogenesis during prolonged hypoglycemia has not yet been determined in humans. The present study represents an extension of previously published data (5) and was therefore undertaken to examine the role of lactate, glycerol, alanine, and glutamine uptake by the kidney in gluconeogenesis during insulin-induced hypoglycemia in humans using arteriovenous balance combined with a tracer technique. ; Cambridge Isotopes, Andover, MA) and a continuous infusion of para-aminohippurate (12 mg/min; Merck, West Point, PA) were started. Subsequently, a dorsal hand vein was cannulated retrogradely and was kept in a thermoregulated Plexiglas box at 65°C for arterialized venous blood sampling (5) . During the 150-min equilibration period, subjects had the left (n = 12) or right (n = 2) renal vein catheterized through the right femoral vein under fluoroscopy, and the position of the catheter tip was ascertained by injecting a small amount of iodinated contrast material. Catheters were advanced as far into the renal vein as possible to minimize blood sampling from left adrenal and gonadal veins. The catheter was then continuously infused with a heparinized saline solution (4.0 U/min) to maintain patency. During the baseline period (-30 to 0 min), 3 consecutive blood samples were collected simultaneously from the dorsal hand vein and the renal vein at 15-min intervals for the determination of para-aminohippurate, insulin, glucagon, catecholamines, plasma glucose concentration, and percentage of enrichment. At 0 min, on completion of baseline collections, subjects were randomized to receive a 180-min continuous peripheral infusion of insulin at the rate of 0.250 mU · kg -1 · min -1 with a concomitant variable infusion of 6-[ 2 H 2 ]dextrose (2% atoms percent excess 10% dextrose in water [DW10]) to achieve and maintain the plasma glucose concentration at either ~5.0 µmol/ml (euglycemic clamp) or ~3.3 µmol/ml (hypoglycemic clamp) and to keep glucose enrichment constant (18) . The insulin infusion rate was selected to produce physiological hyperinsulinemia with mild to moderate hypoglycemia to mimic the evolution of clinical hypoglycemia (2) . Blood samples were again collected from the dorsal hand vein and the renal vein at 15-min intervals between 150 and 180 min. Analytical techniques. Plasma glucose was measured at the bedside with the Beckman II glucose analyzer (Fullerton, CA), and plasma para-aminohippurate concentration (PAH) was determined by a colorimetric method (19) . Plasma insulin (20) and glucagon (21) were determined by radioimmunoassays, and catecholamines were determined by a radioenzymatic method (22 (25) . Blood concentrations of glucose, lactate, alanine, glycerol, and glutamine were determined in triplicate samples treated with 6% perchloric acid (1:1 vol/vol) by an enzymatic assay adapted for the Technicon (Tarrytown, NY) autoanalyzer (26) . The coefficient of variation for single determinations was 2.1% for blood glucose, 2.7% for lactate, 2.6% for alanine, and 3% for glutamine. Calculations. Renal plasma flow (RPF) was calculated by para-aminohippurate clearance using the following (Eq. 1):
where RPF is in milliliters per minute, INF is the para-aminohippurate infusion rate in milligrams per minute, PAH is in milligrams per milliliters, a is artery, and rv is renal vein. Plasma was converted to renal blood flow (RBF) by dividing the RPF (Eq. 1) by the factor (1-hematocrit). Whole-body glucose rate of appearance (R a ) was calculated using the following steady-state formula: (28) . Underestimation of the rate of appearance of unlabeled glucose (R a ) in the systemic circulation related to deficiencies in the monocompartmental equations was minimized by maintenance of an isotopic steady state during the entire experiment (see RESULTS). Endogenous glucose production (EGP) rate was calculated by subtracting the rate of exogenous dextrose infusion from R a in Equation 2. Renal fractional extraction of glucose (FE g ) was calculated using the following:
where [Glu] is the blood glucose concentration, and PE is the [ 2 H 2 ]glucose PE.
Renal glucose utilization (RGU) was calculated using the following:
Net renal substrate balance was calculated according to the following:
where SUB represents blood concentrations of substrates (i.e., glucose, lactate, glycerol, alanine, or glutamine). Positive values indicate net renal uptake, and negative values indicate net renal output. Net renal fractional extraction of substrates was obtained by dividing the arterial substrate concentration by the arterial-renal vein concentration difference. Renal glucose production (RGP) was calculated using the following:
where net [Glu] balance is either net renal glucose uptake or output.
Statistics. All values obtained at baseline and during the experimental period were averaged, and the data are means ± SE for each period. Data obtained at baseline in each group were compared with those in the experimental period with a paired t test. Differences between baseline and study periods in each group were compared using a nonpaired t test. P < 0.05 was considered statistically significant (28) .
RESULTS
RBF was 18.6 ± 2.6 and 17.8 ± 2.0 ml · kg -1 · min -1 at baseline and remained constant during the euglycemic and hypoglycemic clamp studies (18.8 ± 2.8 and 18.3 ± 2.6 ml · kg -1 · min -1 , respectively, P = 0.80). Arterial plasma insulin concentration increased from an average of 49 ± 14 to 102 ± 10 pmol/l and to 130 ± 25 pmol/l (P < 0.001) after insulin infusion at the rate of 0.250 mU · kg -1 · min -1 , respectively, during the euglycemic and hypoglycemic clamp studies. During hypoglycemia, the arterial plasma glucagon concentration increased from 105 ± 6 to 129 ± 8 ng/l (P < 0.05), epinephrine increased 3-fold from 116 ± 28 to 331 ± 33 ng/l (P < 0.001), and norepinephrine increased from 171 ± 9 to 272 ± 9 ng/l (P < 0.01). The arterial plasma glucagon concentration decreased from 95 ± 3 ng/l in the postabsorptive period to 82 ± 3 ng/l (P < 0.05) during the final 30 min of the euglycemic clamp study. Neither arterial plasma epinephrine (74 ± 8 vs. 84 ± 16 ng/l) nor norepinephrine (165 ± 20 vs. 152 ± 22 ng/l) changed significantly during the euglycemic clamp study.
Systemic and renal glucose kinetics in the postabsorptive state and after insulin infusion with either euglycemia or hypoglycemia were analyzed using blood glucose concentrations and RBF (vs. plasma glucose and plasma flow) (5) and are summarized in Tables 1-3 and Figs. 1 and 2. Individual data on blood glucose concentration, PE of glucose, and renal FE g are shown in Tables 1 (euglycemic clamp, n = 8) and 2 (hypoglycemic clamp, n = 6). RGP increased from an average 3.0 ± 0.7 µmol · kg -1 · min -1 in the postabsorptive state to 5.4 ± 0.5 µmol · kg -1 · min -1 during hypoglycemia but decreased to 1.7 ± 0.6 µmol · kg -1 · min -1 during euglycemia (Table 3) . RGU in the postabsorptive state (2.0 ± 0.6 µmol · kg -1 · min during euglycemia (Table 3) . As a consequence, net renal glucose output increased from 1.0 ± 0.3 to 3.3 ± 0.4 µmol · kg -1 · min -1 during hypoglycemia, whereas it reversed to a net uptake of 2.4 ± 0.7 µmol · kg -1 · min -1 during euglycemia (P < 0.01 hypoglycemia vs. euglycemia). Figures 1 and 2 depict changes in mean arterial and renal vein blood glucose concentrations and PE during the entire 180-min period of insulin infusion with either euglycemia (Fig. 1) or hypogly- cemia (Fig. 2) . Blood glucose concentration is consistently higher and PE is consistently lower in the renal vein than in the artery because blood glucose concentrations fell from an average postabsorptive value of 4.5 ± 0.2 mmol/l to a plateau value of 3.0 ± 0.1 mmol/l during the hypoglycemic period. In contrast, during the steady-state euglycemic period (150-180 min), blood glucose concentration in the artery (4.30 ± 0.10 mmol/l) was slightly higher (P < 0.05) than in the renal vein (4.17 ± 0.10 mmol/l), whereas plasma glucose enrichment in the artery (2.31 ± 0.11%) and in the renal vein (2.26 ± 0.11%) were comparable (NS). Table 4 summarizes arterial and renal venous blood concentrations of lactate, alanine, glycerol, and glutamine. Añ 20% increase was evident in arterial lactate, and an ~20% decrease was evident in arterial glycerol concentration during euglycemia, both of which were blunted by hypoglycemia; arterial alanine and glutamine concentrations did not change significantly during either the euglycemic or hypoglycemic clamps. Net renal fractional extraction of lactate did not change during euglycemia (0.13 ± 0.03 vs. 0.13 ± 0.05%, NS) but increased to 0.19 ± 0.5% (P < 0.05) during hypoglycemia. Similarly, net renal lactate uptake did not change during euglycemia (2.4 ± 0.5 vs. 2.8 ± 0.6 µmol · kg -1 · min -1 , NS), but increased to 3.5 ± 0.6 µmol · kg -1 · min -1 (P < 0.05) during hypoglycemia. Net renal fractional extraction of glycerol did not change during euglycemia (0.33 ± 0.08 vs. 0.30 ± 0.07%, NS) but increased to 0.49 ± 0.05% (P < 0.05) during hypoglycemia. Net renal glycerol uptake decreased from 0.6 ± 0.1 to 0.4 ± 0.1 µmol · kg -1 · min -1 (P < 0.05) during euglycemia but increased to 1.3 ± 0.2 µmol · kg -1 · min -1 (P < 0.05) during hypoglycemia. Both net renal fractional extraction of alanine (~0.03 ± 0.01%) and net renal alanine balance (range -0.07 to 0.31 µmol · kg -1 · min -1 ) were negligible in the postabsorptive state and did not change significantly during either the euglycemic or hypoglycemic clamp periods. Net renal fractional extraction of glutamine decreased from 0.07 ± 0.02 to 0.01 ± 0.02% (P < 0.05) during euglycemia but increased to 0.14 ± 0.05% (P < 0.05) during hypoglycemia. Net renal glutamine uptake decreased from 0.7 ± 0.2 to 0.1 ± 0.1 µmol · kg -1 · min -1 (P < 0.05) during eugly- Assuming that renal extraction of these gluconeogenic precursors is entirely diverted toward gluconeogenesis in the kidney, and considering that 2 mol each of lactate, glycerol, and alanine and 1.2 mol glutamine (9) are required for every mole of glucose synthesized de novo, we have estimated the potential contribution of these circulating substrates to RGP (Fig. 3) under these experimental conditions. In the postabsorptive state, circulating lactate could account for 1. ) during hypoglycemia.
DISCUSSION
The present studies confirm previous findings in dogs (14, 15) that indicated that mild to moderate hypoglycemia caused by sustained insulin infusion in humans is accompanied by enhanced renal gluconeogenesis and further demonstrated that utilization of gluconeogenic precursors by the kidney is increased during the process of glucose counterregulation. Renal conversion of circulating lactate, glycerol, and glutamine could account for nearly 60% of all glucose carbons released in the renal vein after 3 h of insulin infusion with sustained blood glucose concentrations of ~3.0 mmol/l. Moreover, our data indicate that alanine conversion to glucose by the kidney (in contrast with that in the liver) is negligible, whereas renal glutamine gluconeogenesis appears to be enhanced in these hypoglycemic conditions. These observations are consistent with the documented limited biochemical capacity of the kidney to produce glucose from alanine (29) and further support the notion of organ substrate selectivity (i.e., that alanine is converted to glucose exclusively by the liver and that glutamine is utilized preferentially by the kidney) (16) . Preferential utilization of alanine by the liver and of glutamine by the kidney may reflect differences in amino acid uptake and transport in each organ. Glutamine transport across tubular cell membranes is hormone sensitive (A system), whereas the N system in hepatocytes is not (30) . Thus, renal (but not hepatic) glutamine transport may be responsive to counterregulatory hormones. Furthermore, in contrast with alanine, glutamine supply to the liver is substantially decreased, considering that portal blood flow accounts for 70% of total hepatic blood flow (31) and that rates of glutamine utilization by portal-draining viscera (particularly the intestines) are very high (32) . The extent to which this reduced load of glutamine (and the correspondingly increased load of alanine) to the liver contributes to organ selectivity is not known. Even though the mechanisms for organ substrate selectivity are not entirely clear, our findings support the notion that systemic tracer measurements of alanine conversion to glucose reflect primarily hepatic gluconeogenesis and that similar measurements of glutamine provide estimates of renal gluconeogenesis. By measuring substrate concentration in blood sampled directly from the renal vein simultaneously with the tracer infusion technique, our data complement previous findings (2) and provide strong evidence that, in humans (analogous to dogs), renal utilization of circulating substrates becomes an additional source of glucose during sustained hypoglycemia. According to our data, circulating lactate represents a major contributor to RGP both in the postabsorptive state and during hypoglycemia. Despite the fact that arterial blood lactate concentrations remained unaltered during hypoglycemia, renal fractional extraction of lactate increased by 50%, which suggests that the increase in net lactate uptake by the kidney results from changes in transport across plasma membranes most likely mediated by counterregulatory hormones. Additionally, an increase in the overall gluconeogenic efficiency in the kidney (15) may have sustained augmented rates of RGP. The contribution to systemic gluconeogenesis of lactate conversion to glucose by the human kidney suggested in these experimental conditions is of particular importance because increased lactate recycling in diabetes is presumed to occur exclusively in the liver (33) , and lactate conversion to glucose in the liver has been shown to be inhibited by antihyperglycemic agents used in the treatment of diabetes (34) . Whether renal gluconeogenesis contributes to lactate recycling in diabetes and whether the process in the kidney (analogous to that in the liver) is responsive to these drugs are currently unknown.
Although hormonal changes in these hypoglycemic conditions are rather mild, increases in net renal fractional extraction of glycerol (50%) and glutamine (100%) (despite minimal changes in blood levels) suggest that enhanced renal gluconeogenesis from circulating substrates during hypoglycemia in humans may be hormonally mediated and not secondary to changes in substrate supply (10) . Our data are consistent with earlier in vivo human studies that indicated that net renal glucose output is increased during fasting (35) and in acidosis (36) despite reduced substrate availability, and our data lend further support to the hypothesis that hepatic and renal gluconeogenesis are regulated by common neurohormonal regulation. Of additional interest, however, is the fact that, because renal glutamine gluconeogenesis is invariably accompanied by ammonia formation (which facilitates acid excretion and restores bicarbonate) (37), the possibility that glutamine gluconeogenesis is driven by mechanisms involved in pH regulation during hypoglycemia cannot be ruled out.
Our calculated rates of renal gluconeogenesis from lactate, glycerol, and glutamine should not be viewed in absolute terms, for various reasons. First, estimation of substrate incorporation into glucose by arteriovenous concentration differences represents a maximum possible contribution and assumes that all circulating precursors extracted by the kidney are diverted into glucose production de novo. Second, although the amount of intracellularly derived substrates available for gluconeogenesis is likely to be negligible, glycerol and glutamine are not formed to a significant extent, and lactate is generated in the distal nephron whereas gluconeogenesis takes place in proximal tubules (10), these techniques do not account for any intracellular sources. Finally, by limiting our analyses to circulating lactate, glycerol, alanine, and glutamine, we were unable to identify the source of the 30-40% of glucose carbons released in the renal vein both in the postabsorptive period and during hypoglycemia. Because the distal nephron lacks glucose-6-phosphatase activity (10), the contribution of glycogen degradation to glucose production by the kidney is presumably insignificant. On the other hand, tracer-determined RGP rates may be systematically overestimated by our methods, which is suggested by discrepancies between our findings and those of other investigators (38) .
Considering that RGP rates are higher in our studies than in those reported by Ekberg et al. (38) in the postabsorptive state, we may have conceivably overestimated RGP rates during hypoglycemia. The fact, however, that increases in RGP detected by the tracer dilution technique closely agree with data obtained by measurements of gluconeogenic precursor extraction during hypoglycemia supports our hypothesis that glucose production by the kidney is enhanced in response to a decrease in blood glucose. According to our data, the kidney may contribute between 30% (gluconeogenic precursor extraction) and 50% (glucose tracer data) of EGP during counterregulation in these mild to moderate hypoglycemic conditions. Similar observations by an independent group of investigators (39) further support our original hypothesis. Our measurements based on whole blood rather than plasma analyses yielded greater rates of glucose production and utilization by the kidney in the same group of individuals. When considering that glucose is exchanged across organs in whole blood, the current data are more likely to reflect true rates of glucose production and utilization than those published earlier (5) . Although the latter represents a significant improvement in our method, a discrepancy between our findings and those of others (38) still remains.
The reasons for discrepant findings in postabsorptive human subjects are not yet entirely clear but can be partially explained by differences in isotopes used (given that the small arterial-renal venous differences in disintegrations per minute counts and in glucose enrichment infusion of higher doses of isotopes with maintenance of higher plasma glucose specific activity and/or enrichments are more likely to detect label dilution than conventional doses), catheterization, and blood sampling techniques (e.g., contamination of the left renal vein by blood draining from the adrenal and gonadal veins could have led to overestimation of left and birenal glucose utilization and production rates, whereas contamination by backflow from the inferior vena cava could have the opposite effect). Moreover, in contrast with a population of male Caucasian subjects studied by Ekberg et al. (38) , in our series, women represented 50% of the study population, and African-Americans and Hispanics together accounted for 40% of all subjects studied. Our subjects are an average of 5 years younger than those reported by Ekberg et al. (38) . The extent to which differences in techniques, age, sex, and ethnic background among subjects in these studies are responsible for some of these discrepant findings cannot be determined at this point. Nonetheless, although the exact contribution of the human kidney to glucose production and utilization in the postabsorptive state remains controversial, the fact that the kidney makes a contribution to postabsorptive EGP has been recently confirmed with the use of highly sensitive isotopes ([U- 13 C]glucose) by 2 independent groups of investigators (38, 40) .
In summary, we have demonstrated that extraction of circulating lactate, glycerol, and glutamine (but not alanine) by the human kidney is enhanced and may account for ~60% of the compensatory rise in RGP, which is equivalent to ~20% of systemic glucose production during sustained mild to moderate hypoglycemia. These findings strongly suggest that increased utilization of circulating substrates directed toward gluconeogenesis by the kidney is an additional mechanism by which the decrease in blood glucose concentration can be attenuated. Our observations further support the notion of organ selectivity with preferential utilization of alanine by the liver and of glutamine by the kidney. We conclude that utilization of circulating gluconeogenic precursors by the kidney is stimulated during counterregulation and represents an additional physiological mechanism in defending against hypoglycemia in humans.
